Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl clinical trials

Explore recruiting relapsed or refractory r r diffuse large b cell lymphoma dlbcl clinical trials.

Recruiting relapsed or refractory r r diffuse large b cell lymphoma dlbcl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Portugal, Hungary, Bulgaria, Poland, Czechia, Croatia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Italy, France, Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl trials by city

Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Toronto Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Vancouver Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Montreal Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Calgary Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Edmonton Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Ottawa Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Winnipeg Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Quebec City Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Hamilton Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Kitchener Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in London Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Halifax Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in New York Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Los Angeles Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Chicago Relapsed Or Refractory R R Diffuse Large B Cell Lymphoma Dlbcl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease